← All trials
NCT04702568
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 18, 2020
- Primary completion
- Oct 31, 2024
- Completion date
- Jan 31, 2025
- First posted
- Jan 11, 2021
- Last posted
- Jan 11, 2021
- Enrollment
- 200
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- BioCrystLead sponsor
- University of LeedsOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.